AVCRF Avricore Health Inc (QB)

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

                                                              FORM 12b-25

                                                      NOTIFICATION OF LATE FILING

(Check One): [    ] Form 10-K      [X]  Form 20-F    [  ] Form 11-K    [X]  Form 10-Q    [  ] Form N-SAR

For Period Ended:    12/31/2017                    

[  ] Transition Report on Form 10-K

[  ] Transition Report on Form 20-F

[  ] Transition Report on Form 11-K

[  ] Transition Report on Form 10-Q

[  ] Transition Report on Form N-SAR

For the Transition Period Ended: ______________________

Read Instruction (on back page) Before Preparing Form.  Please Print or Type.

Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.

If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:

____________________________________________________________________________________________

PART I -- REGISTRANT INFORMATION

VANC Pharmaceuticals Inc.                                                                                                                      Full Name of Registrant

Not Applicable __________________________________________ Former Name if Applicable

810 – 789 West Pender Street                                                                                                              Address of Principal Executive Office (Street and Number)

Vancouver, BC  V6C 1H2                                                                                                                     City, State and Zip Code

PART II -- RULES 12b-25(b) AND (c)

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief

pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)

x

(a) The reasons described in reasonable detail in Part III of this form could not be eliminated without       unreasonable effort or expense; (b) The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, 11-K or       Form N-SAR, or portion thereof, will be filed on or before the fifteenth calendar day following the       prescribed due date; or the subject quarterly report of transition report on Form 10-Q, or portion       thereof will be filed on or before the fifth (c) The accountant's statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

PART III -- NARRATIVE

State below in reasonable detail the reasons why Forms 10-K, 20-F, 11-K, 10-Q, N-SAR, or the transition report

portion thereof, could not be filed within the prescribed time period.                ( Attach Extra Sheets if Needed)

The Company is unable to file its annual report on Form 20-F for the period ended Dec. 31, 2017 within the

prescribed time period without unreasonable effort or expense.  Management deems it necessary that additional time

be taken in order to ensure that complete, thorough and accurate disclosure of all material information is made in its

20-F Report.  The Company expects to file its Form 20-F within the 15 calendar day period described in Part II (b) above.

---

PART IV -- OTHER INFORMATION

(1) Name and telephone number of person to contact in regard to this notification

           Dong Shim                                                    604                                  687-2038           

              

               (Name)                                             (Area Code)                 (Telephone Number)

(2)  Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or

      Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period

      that the registrant was required to file such report(s) been filed?  

      If answer is no, identify report(s).   [] Yes    [ X ] No   Form 6K

(3)  Is it anticipated that any significant change in results of operations from the corresponding period for the last

      fiscal year would be reflected by the earnings statements to be included in the subject report or portion thereof?

        [  ] Yes     [ X ]  No

     If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state

     the reasons why a reasonable estimate of the results cannot be made.

__________________________________________

Vanc Pharmaceuticals Inc.

has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

Date:   April 30, 2018        

                                             By:

“Dong “Shim”                             

Dong Shim, Chief Financial Officer

INSTRUCTION: The form may be signed by an executive officer of the registrant of by any other duly authorized

representative.  The name and title of the person signing the form shall be typed or printed beneath the signature.  If

the statement is signed on behalf of the registrant by an authorized representative (other than an executive officer),

evidence of the representative's authority to sign on behalf of the registrant shall be filed with the form.

ATTENTION

International misstatements or omissions of fact constitute Federal Criminal Violations (See 18 U.S.C. 1001).

GENERAL INSTRUCTIONS

1. This form is required by Rule 12b-25 (17 CFR 240.12b-25) of the General Rules and Regulations under

    the Securities Exchange Act of 1934.

2. One signed original and four conformed copies of this form and amendments thereto must be completed

    and filed with the Securities and Exchange Commission, Washington, D.C. 20549, in accordance with

    Rule 0-3 of the General Rules and Regulations under the Act. The information contained in or filed

    with the form will be made a matter of public record in the Commission files.

3. A manually signed copy of the form and amendments thereto shall be filed with each national

    securities exchange on which any class of securities of the registrant is registered.

4. Amendments to the notifications must also be filed on form 12b-25 but need not restate information

    that has been correctly furnished. The form shall be clearly identified as an amended notification.

5. Electronic filers .  This form shall not be used by electronic filers unable to timely file a report

    solely due to electronic difficulties. Filers unable to submit a report within the time period

    prescribed due to difficulties in electronic filing should comply with either Rule 201 or Rule 202 of

    Regulation S-T (§232.201 or §232.202 of this chapter) or apply for an adjustment in filing date

    pursuant to Rule 13(b) of Regulation S-T (§232.13(b) of this Chapter).